858 Therapeutics is a biotechnology company focused on developing small molecule therapeutics aimed at novel oncology targets. Founded in 2019, this San Diego-based enterprise has garnered significant attention in the biotech sector. The firm concentrates on pioneering treatments in the realms of cancer and immune diseases. Having raised notable funding through investors such as Versant Ventures and Logos Capital, the company has established itself as a significant player in innovative drug development.
April 2024: 858 Therapeutics received attention for a planned presentation at the American Association for Cancer Research (AACR) 2024 Annual Meeting. They are set to showcase preclinical data on their lead compound, ETX-19477, a novel PARG inhibitor with high potency against tumors experiencing replication stress. The company aims to begin a Phase I clinical trial soon to test its effectiveness in humans with advanced solid tumors.
September 2024: The company raised $50 million in Series B financing to further the development of ETX-19477 and continue the growth of its drug pipeline. This fundraising effort is crucial for supporting ongoing clinical trials and expanding research initiatives.
December 2023: In a strategic move to bolster its clinical capabilities, 858 Therapeutics appointed Dr. Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer. This addition underscores the company's focus on supporting its leadership team with individuals who have extensive clinical development experience in oncology.
2023: 858 Therapeutics expanded its leadership team to strengthen its transition from preclinical research to clinical trials. The company aims to optimize its operations and resources to support more rapid clinical development activities.
| Attribute | Information |
|---|---|
| Founding Date | 2019 |
| Headquarters | San Diego, California, USA |
| Founders | Jeffrey Stafford, Ph.D. (CEO and Co-founder) |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Versant Ventures, NEA, Cormorant Asset Mgmt, Logos Capital |
| Industry | Biotechnology and Pharmaceuticals |
| Number of Employees | Approx. 40 |
858 Therapeutics began its journey in 2019, founded by experienced professionals from the biotech industry like Jeffrey Stafford. The company's inception was marked by a $60 million Series A financing round led by Versant Ventures and other prominent investors, setting a solid foundation for its mission to develop innovative oncology treatments. The vision was to harness scientific advancements in oncology to address unmet clinical needs, particularly targeting RNA pathways and epigenetic modulation of cancer cells.
858 Therapeutics operates at the cutting-edge intersection of biotechnology and drug discovery, with a pronounced focus on oncology. Its distinct business model centers on identifying and exploiting unique therapeutic targets in cancer biology, such as RNA modulation and DNA repair mechanisms.
Key Achievements:
Currently, 858 Therapeutics is advancing its pipeline of small molecule therapeutics, primarily focusing on their PARG inhibitor, ETX-19477. As a clinical-stage company, 858 holds a competitive position in the oncology domain, driven by advanced research capabilities and strategic financing. The company continues to amplify its market stance through substantive partnerships and investment rounds, thereby aligning its operations with growth opportunities across the biotechnology landscape.
858 Therapeutics has swiftly positioned itself as an innovative player in biotechnology, particularly in developing therapeutics for cancer. With ongoing advancements in its drug pipeline and strategic financing rounds, the company aims to bring impactful solutions to patients with challenging oncological conditions. As clinical trials unfold, 858 Therapeutics has the potential to make significant contributions to oncology and expand its influence in the biotech arena.